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We investigated the correlation between the expression and localisation of Akt-1, Akt-2, Akt-3, phospho-Akt proteins and the
clinicopathological parameters in 63 prostate cancer specimens. More than 60% of cancerous tissues overexpressed Akt-1, Akt-2 or
Akt-3. Cytoplasmic Akt-1 expression was correlated with a higher risk of postoperative prostate-specific antigen (PSA) recurrence
and shorter PSA recurrence interval. Cytoplasmic Akt-2 did not show any significant correlation with clinicopathological parameters
predicting outcomes. Cytoplasmic Akt-3 was associated with hormone-refractory disease progression and extracapsular invasion.
Nuclear Akt-1 and Akt-2 expression were correlated with favourable outcome parameters such as absence of lymph node and
perineural invasion. Kaplan–Meier analysis and Cox regression model also showed that Akt-1 and Akt-2, but not Akt-3 or phospho-
Akt was associated with a significantly higher risk of PSA recurrence. In contrast, nuclear Akt-1 was significantly associated with a
lower risk of PSA recurrence. Multivariate analysis revealed that clinical stage, Gleason score and the combined cytoplasmic nuclear
Akt-1 marker in cancerous tissues were significant independent prognostic factors of PSA recurrence. This is the first report
demonstrating in patients with prostate cancer and the particular role of Akt-1 isoform expression as a prognostic marker depending
of its localisation.
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In mammals, three genes have been identified encoding for the
isoforms of the serine/threonine protein kinase B family, or Akt.
Members of this family, Akt-1, Akt-2 and Akt-3, share 80%
homology. Akt is a signalling component of the tyrosine kinase
growth factor receptors and G-coupled receptors. These receptors
engage the heterodimeric phosphoinositol 3-kinase (PI3K), which
phosphorylates phosphatidylinositol-4, 5-bisphosphate to convert
PIP2 to PIP3. PIP3 levels are tightly regulated by the phosphatase
PTEN, which removes phosphate from the 3-OH position. Then
PIP3 recruits other signalling components such as Akt and PDK.
PDK then phosphorylates and activates Akt, which in turn
regulates downstream signalling proteins involved in cell survival,
cell growth, cell cycle progression and apoptotic response
(Vanhaesebroeck and Alessi, 2000). Akt/PI3K signalling is often
disregulated in human cancer mainly due to constitutive activation
of growth factor receptors and loss of PTEN function. Accumulat-
ing evidence shows a central role of Akt in tumour development
and response to cancer treatment (Wendel et al, 2004).
Although there are a limited number of studies, it seems that all
three isoforms are ubiquitously expressed but the level of
expression of each isoform may differ among tissues thus
modulating in part their biological activities. For example, Akt-1
is more highly expressed in tissues such as brain, thymus and
lungs, whereas Akt-2 gene amplification has been found in
ovarian, breast and pancreas tumours where it has been implicated
in the process of invasion and metastasis (Bellacosa et al, 1995,
2005). Akt-3 is predominantly expressed in brain, heart and kidney
and seems to be responsible for the survival of melanoma cells
(Stahl et al, 2004; Bellacosa et al, 2005).
In prostate cancer cell lines, the constitutive activity of Akt is
mainly due to the constitutive activation of EGFR (Le Page et al,
2005) and PDGFR (Dolloff et al, 2005) in association with a loss of
PTEN (Dong et al, 1998; Gray et al, 1998; Suzuki et al, 1998). This
activity has been associated with advance cancer stage, resistance
to apoptosis through NF-kB activation (Li and Sarkar, 2002; Raj
et al, 2004), downregulation of PTEN and P27 (Graff et al, 2000;
Murillo et al, 2001; Ayala et al, 2004). In clinical specimens, the
overexpression and activation of Akt has been associated with high
preoperative prostate-specific antigen (PSA) level, higher Gleason
grades and shorter disease relapse (Malik et al, 2002; Liao et al,
2003; Ayala et al, 2004; Kreisberg et al, 2004). However, none of
these studies have investigated which isoform(s) is associated with
these phenomena. In fact, the specific expression and role of Akt-1,
-2 and -3 in prostate cancer tissues is still scant. Only one study has
investigated the mRNA level of the isoforms (Zinda et al, 2001) but
did not examine the protein expression or the activity of each
isoform. From studies examining prostate cancer cell lines, some
evidence suggests that Akt isoforms are differentially regulated in
prostate cancer cells and may have different roles. For example,
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sAkt-3 is not expressed in androgen receptor positive prostate cell
lines and no constitutive activation of Akt-2 has been observed in
prostate cancer cell lines while Akt-1 is constitutively activated in
most prostate cancer cell lines (Nakatani et al, 1999). As it is still
unknown if the same pattern occurs in prostate cancer tissues,
analysis of Akt expression is necessary. A better knowledge of Akt
expression and its role will clarify their redundant or comple-
mentary function in cancer progression.
Here, we examined the expression and localisation of the three
isoforms of Akt on tissue arrays containing 373 tissue cores from
63 prostate cancer patients. We also analysed the correlation and
association between expression of each isoform, the presence of
Akt activity and clinical parameters in order to determine whether
the three Akt isoforms are associated with specific parameters in
prostate cancer progression.
MATERIALS AND METHODS
Patient cohort
Paraffin-embeded human primary prostate cancer specimens from
patients having provided informed consent and operated from
1993 to 2000 were reviewed. In total, 64 specimens were included
in our study to create a tissue array. Criteria for the retrospective
cohort study to create the tissue arrays were: no preoperative
treatment was used in this cohort, and all cases had clinical follow-
up of at least 5 years or until death. Patients were followed for an
average range of 72 months. No age difference was observed
between the group of patients who relapsed and the group that did
not. Preoperative PSA level was available for 62 patients.
Postoperative PSA was available for all patients. PSA nonfailure
was defined as PSA remaining below 0.3ngml
 1 after radical
prostatectomy. Recurrence-free interval was defined as the time
between date of surgery and the date of first PSA increase above
0.3ngml
 1. The final staging, grading and histologic diagnosis was
based on the Hospital Notre-Dame (Montreal, QC, Canada)
pathology report in agreement with the review from an
independent pathologist. Ethics approval was obtained from the
local IRB committee.
Tissue arrays, immunohistochemistry and scoring
Tissue arrays containing a total of 384 cores of prostate tissues
(Table 1) were built and used for IHC studies. One normal and two
cancerous cores per patient were spotted on one array and a
duplicate of this array was made, making a total of six cores per
patients. An expert pathologist determine the cancerous, non-
neoplasic prostatic epithelium and PIN areas reviewed H&E-
stained arrays. Eleven cores that contained neither cancerous
tissues nor non-neoplasic adjacent tissues were not considered for
further analysis. The final analysis contained 373 tissue cores
representing 63 patients. No patient was represented by less than
two cores.
The following amounts and antibodies were used in immuno-
histochemistry (IHC): a 1
75 dilution of anti-Akt-1 (D17), a 1
100
dilution of anti-Akt-2 (F7), a 1
20 dilution of Akt-3 (M14) (all from
Santa Cruz Biotechnology, CA, USA) and a 1
25 dilution of phospho-
Akt (#9277) (Cell Signaling, Danvers, MA, USA). Briefly, tissue
arrays were deparaffinised in toluene and rehydrated in a gradient
of ethanol. Subsequently, endogenous peroxidase activity was
quenched by treatment with 0.3% H2O2/methanol. To unmask
antigen the slides were submerged in 951C citrate solution (pH 6.0)
for 15min. The tissues were blocked for 15min with a protein-
blocking serum-free reagent (Dako Cytomation Inc., Mississauga,
ON, Canada) and incubated with the different antibodies for
60min at RT in a humid chamber. The optimal concentration for
each primary antibody was determined by serial dilutions. The
arrays were then incubated with a secondary biotinylated antibody
(DakoCytomation Inc., Mississauga, ON, Canada) for 15min
followed by incubation with a streptavidin–peroxidase complex
(Dako Diagnostics Canada Inc.). Reaction products were devel-
oped using diaminobenzidine (brown stain) containing 0.3% H2O2
as a substrate for peroxidase. Nuclei were counterstained with
diluted haematoxylin (blue stain). Tumour sections were inspected
at  20 and  40 magnification. Epithelial zones were scored
according to the intensity of staining of the cytoplasm, nucleus or
membrane (value of 0 for absence, 1 for weak, 2 for moderate, 3 for
high intensity). In cores where staining was of variable intensity
the average intensity was reported. Each array was independently
analysed in a blind study by two independent observers. Inter-
rating correlation was 495%. When strong differences in scoring
between the two observers (more than 1unit per core) occurred
the core was re-evaluated to reach a concordant scoring between
the two observers. The average of cancerous scores of the same
patient was used for analysis. No decrease in staining intensity on
older paraffin blocks was observed.
Statistical analysis
Statistical analysis was performed with SPSS software 11.0 (SPSS
Inc. Chicago, IL, USA). To avoid a bias due to different efficiency
of antibody hybridisation on different array slides we calibrated
each slide for interslide comparison. The Spearman correlation
coefficient test (two tailed) was used to estimate the correlation
with clinicopathologic variables. Prostate-specific antigen recur-
rence-free survival curves were plotted using the Kaplan–Meier
analysis and the log-rank test was used to test for significant
differences. Receiver operative characteristic (ROC) curves were
used to determine the threshold value for each Akt marker. Cox
univariate and multivariate proportional hazard models were used
Table 1 Prostate cancer patients cohort
Age median (min–max) 62 (49–70)
Stage
Stage 2 34
Stage 3 29
Invasion
Extracapsular invasion 19
Lymph node invasion 9
Perineural infiltration 9
Hormone refractory disease 5
Prostatis 1
Gleason score
Gleason 4 7
Gleason 5 14
Gleason 6 14
Gleason 7 18
Gleason 8–9 10
Preoperative PSA
o10ng 35
410ng 25
Not available 2
PSA relapse
Relapse 35
No relapse 28
Surgical margins
Negative 31
Positive 32
Survival 54
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sto estimate the hazard ratios for each marker. Multivariate analysis
was performed using a forward stepwise hazard model on
univariate analysis required for entry into the model. Categorical
variables for the model included surgical margins, extracapsular
invasion status, perineural infiltration, preoperative PSA level,
Gleason score, stage, grade and lymph node metastases.
Western blot analysis
Cells were lyzed with cold lysis buffer (10mM Tris-HCl, pH 7.4,
150mM NaCl, 1mM EDTA, 1mM DTT/1mM NaF/0.5% NP-40/
0.5mM PMSF/0.2mM sodium orthovanadate/2mgml
 1 of aprotinin,
leupeptin and pepstatin), boiled in loading buffer, separated by
10% SDS–PAGE, and transferred on a nitrocellulose membrane
under refrigerated conditions (200mA, 2h). Membranes were
saturated with 5% milk/TBS/0.1% Tween-20. Immunodetection was
performed as described in the protocol of the ECL kit (Amersham
Pharmacia, Amersham Biosciences, Backinghamshire, UK): that is
incubated 2h at room temperature with the specific Akt antibodies
(1 to 2mgml
 1), washed two times with TBS/0.1% Tween-20 and
incubated for another 30min at room temperature with peroxidase-
conjugated antibodies (Santa-Cruz Biotechnology, CA, USA).
RESULTS
Akt expression and localisation in normal and cancer
tissues
In total, 373 prostate cancer tissues from 63 cancer prostate
patients spotted on tissue microarrays (Table 1) were evaluated for
Akt-1, -2, -3 expressions by IHC using isoform-specific antibodies.
In agreement with previous studies (Vasko et al, 2004; Kirkegaard
et al, 2005) the specificity of each antibody has been confirmed by
IHC using blocking peptides (Figure 1A) and by Western blot by
comparing NIH 3T3 cells, known to express low level of Akt-1 and
Akt-2 but strong level of Akt-3, with MCF-7 cells that do not
expressed Akt-3 (Figure 1B). Non-neoplasic (n¼141) and
cancerous (n¼232) cores were separately examined. The three
isoforms were expressed in all normal and cancerous tissues with
the exception of one patient showing no expression of Akt-1 and
Akt-2 but weak expression of Akt-3, and another patient showing
no expression of Akt-3 and weak expression of Akt-2 and Akt-1.
Akt isoforms were mainly localised in the cytoplasm and
membrane. In addition, several tissues also presented nuclear
localisation of Akt-1 and Akt-2 but not Akt-3 (Figure 2C). Nuclear
localisation was independent of the cytoplasmic intensity of
staining. In addition to this general pattern, Akt-3 and less often
Akt-2, were also strongly expressed in the basal cell layer
(Figure 2A).
Independent of localisation, the three isoforms were signifi-
cantly overexpressed in cancerous areas as compared to adjacent
non-neoplasic areas (Po0.001, Students’ t-test). Approximately 60,
65 and 59% of cancerous tissues expressed high levels of Akt-1, -2,
-3, respectively, compared to normal adjacent cores while 30% of
normal tissue cores showed a high expression of either Akt-1,
Akt-2 or Akt-3. In addition, in normal and cancerous cores a
strong correlation between expression of phospho-Akt and the
three isoforms was also observed (r¼0.70, 0.75, 0.65, Po0.001,
Spearman’s test).
Correlation between cytoplasmic Akt in cancerous tissues
and clinical parameters
We assessed the correlation between the high expression of each
Akt isoform and clinicopathologic parameters available for
patients: Gleason score, surgical grade, pathological stage, extra-
capsular invasion, perineural infiltration, preoperative PSA level,
PSA relapse time, hormone-refractory cancer progression after
surgery and nodal metastasis status at time of surgery (Table 1).
Overexpression of Akt was determined to be cases that stained
above the median expression of cancerous cores on the tissue
array. First, we analysed the cytoplasmic staining. As shown in
Table 2, in cancerous tissues, no correlation was observed between
Akt-1, -2, or -3 and Gleason score, surgical grade or pathological
stage. Akt-1 expression tended to positively correlate with
preoperative PSA level (r¼0.24, P¼0.06, Spearman’s test).
However, a significant stronger Akt-1 staining was obtained in
patients with preoperative PSA410ng (P¼0.046, Mann–Whitney
U-test). We also noticed a weak trend of cytoplasmic Akt-1
expression to correlate inversely with PSA recurrence-free interval
(r¼ 0.28, P¼0.10, Spearman’s test).
Although, no correlation was observed between cytoplasmic
Akt-2 and clinical parameters tested (Table 2), cytoplasmic Akt-3
correlated with resistance to hormone therapy (r¼0.34, P¼0.01,
Spearman’s test) and showed a tendency to correlate with
extracapsular invasion (r¼0.23, P¼0.07, Spearman’s test). A
correlation between cytoplasmic Akt-3 and PSA relapse interval
was also observed (r¼ 0.23) but was not significant (P¼0.20).
Correlation between nuclear Akt in cancerous tissues and
clinical parameters
Inversely to its cytoplasmic expression, the nuclear staining of
Akt-1 in cancerous tissues directly correlated with PSA relapse
time (r¼0.40, P¼0.02, Spearman’s test, Table 2), and negatively
with perineural infiltration (r¼ 0.38, Po0.01). In contrast,
nuclear Akt-2 in cancerous tissues was not significantly associated
with any parameter tested, but only showed a trend to correlate
inversely with perineural infiltration and lymph node invasion
(r¼ 0.22, P¼0.08, Table 2).
Akt-1 and Akt-2 in cancerous tissues are associated with
PSA relapse
As overexpression of cytoplasmic Akt-1 and Akt-3 in cancerous
tissues was correlated with PSA recurrence-free interval, we
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Figure 1 Validation of Akt-specific antibodies by IHC and Western blot.
(A) Immunohistochemistry staining was performed using antibodies against
Akt-1, Akt-2, Akt-3 with or without corresponding and not corresponding
blocking peptides as indicated. Notice that the specific peptide for the
corresponding antibody abolishes or reduces the staining of cancerous
areas while the nonspecific peptides reduce the staining only in stroma
areas but not in cancerous areas. (B) Expression of Akt in different cell
lines: NIH 3T3 show low expression of Akt-1 and Akt-2 but higher
expression of Akt-3 while MCF-7 and LNCaP cells show no expression of
Akt-3 but expression of Akt-1 and Akt-2. Cell lysates were subjected to
Western blotting and revealed using specific Akt isoform antibodies as
indicated.
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sperformed Kaplan–Meier analysis and Cox proportional
hazard model to estimate the association between overexpression
of Akt-1, Akt-2 or Akt-3 and PSA relapse. For comparison
purpose, we also considered expression of the active form
of Akt (phospho-Akt) that has previously been described
as a significant predictor of PSA relapse (Ayala et al, 2004;
Kreisberg et al, 2004). Receiver operative characteristic curves
were used to estimate an optimal threshold values for the
cytoplasmic markers that could be used to predict PSA failure.
Nuclear Akt-1 and Akt-2 were categorised by their presence
or absence. Consistent with the correlations previously observed in
cancerous tissues, the overexpression of cytoplasmic Akt-1 was
significantly associated with earlier PSA relapse (P¼0.04, log rank
test, Figure 3A and Table 3). In addition, Akt-2 was also
significantly associated with earlier PSA relapse (P¼0.02, log
rank test, Figure 3B and Table 3) while Akt-3 and phospho-Akt
were borderline significant (P¼0.07, P¼0.06, respectively, log
rank, Table 3, Figure 3C and D). In univariate analysis a slightly
increased risk of relapse was associated with these markers
(Table 4). Akt-2 showed a slightly higher risk of relapse than Akt-1
(Table 4).
Nuclear Akt-1 in cancerous tissues was significantly associated
with a longer interval for PSA relapse (P¼0.03, log rank test,
Table 3), but not nuclear Akt-2. The median relapse time of
patients without nuclear Akt-1 was 32 months compared to 82
months for patients with nuclear Akt-1 (Figure 3E). The 2.24-fold
decrease in the risk of relapse (hazard ratio, P¼0.05, Table 4)
confirmed a protective effect of nuclear Akt-1.
As no significant correlation was observed between the presence
of nuclear Akt-1 and the intensity of Akt-1 cytoplasmic staining
(P¼0.67, r¼0.05, Spearman’s test), we tested the hypothesis that
combining both markers may be more informative and help
predict risk group. A high-risk patient group (high cytoplasmic
Table 2 Spearman correlation test (two tailed) between Akt expression in cancerous tissues and clinical parameters
Cytoplasmic Nuclear
Akt1 Akt2 Akt3 p-Akt Akt1 Akt2 p-Akt
Spearmann rPr PrPrPr P rPr P
Hormone-refractory disease 0.02 0.87  0.06 0.62 0.34 0.01  0.05 0.73  0.01 0.96  0.05 0.71  0.18 0.15
Preoperative PSA 0.24 0.06 0.09 0.48 0.11 0.4 0.28 0.03 0.09 0.5 0.22 0.09  0.03 0.82
Gleason score  0.046 0.72  0.16 0.21 0 1  0.07 0.58  0.15 0.23  0.1 0.56  0.05 0.7
Extracapsular invasion  0.067 0.6 0.09 0.47 0.23 0.07  0.07 0.57  0.03 0.79  0.09 0.43 0.16 0.2
PSA relapse  0.28 0.1 0.07 0.68  0.23 0.2 0.17 0.33 0.4 0.02  0.03 0.86  0.09 0.5
Stage  0.04 0.76  0.05 0.72 0.17 0.18  0.12 0.37  0.12 0.35  0.08 0.54 0.08 0.53
Grade  0.07 0.59  0.12 0.34  0.07 0.59  0.07 0.59  0.15 0.25  0.14 0.27  0.07 0.59
Survival 0.07 0.6 0.04 0.76  0.1 0.42  0.12 0.36  0.02 0.9  0.07 0.58 0.02 0.87
Lymph node invasion  0.03 0.83 0.04 0.76  0.1 0.42  0.21 0.1  0.033 0.8  0.22 0.08 0.04 0.76
Perineural infiltration 0.16 0.21  0.14 0.27  0.1 0.42 0.16 0.21  0.38 o0.01  0.22 0.08 0.04 0.76
r¼correlation coefficient. Correlation r40.20 are indicated in bold.
Akt-1 Akt-2 Akt-3 p-Akt
Morphologically normal areas
from cancer patients
Cancerous areas
Nuclear staining
Cytoplasmic staining
A
B
C
Figure 2 Expression and localisation of Akt-1, -2 and -3 in prostate cancer tissues. Immunohistochemistry staining was performed using specific antibodies
against Akt-1, Akt-2, Akt-3 or phospho-Akt as indicated. (A) Staining normal. (B) Cytoplasmic expression in cancerous areas. (C) Nuclear staining in
cancerous areas. Notice the basal cell staining by anti-Akt-1 and anti-Akt-2 antibodies. Magnification  40. Arrows show basal cell staining.
Table 3 Significance of Akt staining and association with PSA relapse or
survival
PSA relapse Survival
Tissue Marker Localization PP * PP *
Cancer Akt1 Nucleus 0.03** 0.05 0.68 0.69
Cytoplasm 0.04** 0.04 0.72 0.73
Akt2 Nucleus 0.74 0.74 0.43 0.46
Cytoplasm 0.02** 0.03 0.79 0.79
Akt3 Nucleus NA NA NA NA
Cytoplasm 0.07** 0.08 0.85 0.85
p-Akt Nucleus 0.88 0.88 0.35 0.35
Cytoplasme 0.06** 0.06 0.64 0.64
Combined Akt1 Nucleus/cytoplasmic 0.002 0.001 0.49 0.99
P¼log rank test. P*¼univariate Cox regression model; PSA¼prostate-specific
antigen. **Kaplan–Meier graph are shown in Figure 3. Bold values highlight significant
association.
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sAkt-1 and absence of protective nuclear Akt-1), a low-risk patient
group (low Akt-1 cytoplasmic and the presence of protective
nuclear Akt-1) and an intermediate group composed of the
remaining patients. As predicted, the high-risk patient group
showed a significant lower mean PSA relapse interval (13 months),
while the low-risk patients showed a significant higher mean PSA
relapse interval (73 months) compared to the intermediate group
(68 months) (P¼0.002, log rank test, Figure 3F). In another words
all high-risk patients had a PSA recurrence before 2 years while
intermediate risk patients had recurrence with variable interval
(40% before 2 years) and most low-risk patients (20 out of 22) had
PSA relapse after 2 years.
In multivariate analysis, when representative prognostic
variables of univariate significance were undertaken (surgical
margins, extracapsular invasion, perineural infiltration, Gleason
score, lymph node invasion and pathologic stage and surgical
grade, PSA level and Akt markers), only the combination of
cytoplasmic and nuclear Akt-1 markers, Gleason score and stage
remained independent predictive variables of PSA relapse with the
pathologic stage showing the highest risk of relapse (Table 4).
Akt is not associated with survival
In addition to the association with PSA-relapse, we also tested the
association between each isoform of Akt and survival. Kaplan–
Meier analysis and Cox regression hazard model demonstrated no
significant association between Akt and survival given the
relatively low mortality rate in this cohort of radical prostatectomy
patients (Figure 3 and Table 4).
DISCUSSION
In men, prostate cancer is the most frequently diagnosed cancer
and a leading cause of cancer death. Unfortunately, the cellular
events responsible for progression to hormone-independent
prostate cancer are not yet well known. There are no reliable
molecular markers that predict if a cancer will progress to an
aggressive disease. Recently, attention has focused on the activity
of the protein kinase Akt due to its role in cell survival,
proliferation, apoptosis and its association with PSA relapse in
prostate cancer patients (Graff, 2002). However, the precise
involvement of Akt in prostate cancer progression is not well
defined and in particular it is not known if all three isoforms are
associated with disease progression and have the same role in
prostate cancer progression. Here, we investigated the correlation
between the level of each Akt isoform and different clinical
parameters. Even if the signalling role of Akt is exerted only when
the kinase is activated by phosphorylation, we expect that the
amount of each isoform reflects their respective activity level since
no differential affinity of the upstream activator PDK for the
different Akt has been reported to date. The correlation between
levels of expression and downstream activation is further
supported by in vitro studies in cell lines (Nakatani et al, 1999).
Interestingly, we found that the expression of Akt-1, Akt-2 and
Akt-3, did not correlate with the same clinical parameters
suggesting that different Akt isoforms may have different and
specific roles. This hypothesis is reinforced by the fact that the
phospho-Akt staining, which is unable to dissociate the different
isoforms, did not show any strong correlation with these
parameters. Similar results have recently been reported where
only a weak correlation between phospho-Akt expression and
clinical stage was observed (Ayala et al, 2004). In addition, our
study found that Akt-1 and phospho-Akt overexpression in
cancerous tissues was correlated with a high preoperative PSA
level. This result is consistent with a previous study where a
significant difference in the intensity of Pan-Akt staining in
tumours from patients with high and low PSA level was observed
(Liao et al, 2003). In contrast, Akt-3 expression correlated with
extracapsular invasion and hormone-refractory disease progres-
sion, suggesting that Akt-3 is involved in the invasion potential of
prostate cancer cells, and may therefore play a role in later stages
of the disease. More in vitro and in vivo studies are needed to
support this hypothesis. In our cohort, the number of patients
progressing to a hormone-refractory disease was relatively small
and the role of Akt-3 in hormone therapy resistance should be
estimated on a larger scale.
Surprisingly, we also found an inverse correlation between
nuclear and cytoplasmic Akt-1 and clinical parameters. High
cytoplasm expression of Akt-1, and also Akt-3, was correlated with
poor prognosis parameters, such as elevated preoperative PSA
levels, earlier PSA relapse, hormone-refractory disease progres-
sion, extracapsular invasion while the presence of Akt-1, and
Akt-2, in the nucleus of normal or cancerous tissues was correlated
with better prognosis parameters such as later PSA relapse and
absence of perineural infiltration. Similarly, the presence of
nuclear Akt has also been correlated with good prognosis in lung
cancer, endometrial carcinoma and superficial spreading melano-
ma (Shah et al, 2005; Slipicevic et al, 2005; Uegaki et al, 2005).
These observations are reinforced by the combined effect of
nuclear and cytoplasmic Akt-1 markers on recurrence disease, as
seen on Figure 3. These results suggest that compartementalisation
of Akt may be important in determining its cellular effect. In
different cancers, activation of Akt acts by phosphorylation of
transcription factors, signalling components such as IKK, caspase
9, mTor, Bad and others. Although most of these targets are
phosphorylated in the cytoplasm, some appear to be phosphory-
lated in the nucleus (Liang et al, 2002; Nicholson and Anderson,
2002; Shin et al, 2002; Viglietto et al, 2002). In prostate cancer, Akt
has been shown to modulate by phosphorylation the activity and
stabilisation of the nuclear androgen receptor (Lin et al, 2001,
2002). It is thus tempting to speculate that nuclear Akt-1 or Akt-2
can phosphorylate nuclear AR to reduce its expression and
androgen growth response of cells. In contrast, when Akt is absent
from the nucleus higher AR level can induce androgen-dependent
growth favouring disease progression, which would correlate with
a shorter disease relapse as observed in the present study.
The prognostic significance of each isoform of Akt has
not been examined in other cancers from chemotherapy-free
patients. In contrast phospho-Akt has been examined in a number
of other cancers, although different results were obtained
Table 4 Prognostic factors predicting PSA relapse in prostate cancer
cohort of 63 patients
PSA relapse Hazard ratio (95% CI) P
Univariate
Stage 5.419 (2.627–11.179) o0.001
Grade 2.025 (1.193–3.436) 0.009
LN invasion 2.02 (0.88–4.634) 0.097
Preneural infiltration 2.250 (0.982–5.153) 0.055
Extracapsular invasion 3.332 (1.713–6.481) o0.001
Gleason score 1.514 (1.168–1.963) 0.002
Margins 5.372 (2.498–11.551) o0.001
Akt1 cytoplasmic 2.032 (1.014–4.074) 0.05
Akt1 nuclear 2.242 (1.047–4.808) 0.04
Akt2 cytoplasmic 2.406 (1.094–5.290) 0.03
Akt3 cytoplasmic 1.908 (0.938–3.883) 0.08
p-Akt cytoplasmic 1.867 (0.964–3.612) 0.06
Akt-1 cytoplasmic/nuclear 2.722 (1.496–4.953) 0.001
Multivariate
Stage 3.581 (1.63–7.87) o0.001
Akt-1 cytoplasmic/nuclear 2.118 (1.12–3.99) 0.02
Gleason score 1.357 (1.01–1.82) 0.04
Cox regression models. CI¼confidence interval; PSA¼prostate-specific antigen. Akt
staining corresponds to staining in cancerous tissues.
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renal and head and neck carcinoma, phospho-Akt is associated
with cancer recurrence (Perez-Tenorio and Stal, 2002; Horiguchi
et al, 2003; Kirkegaard et al, 2005). In gliomas, and ovarian cancer
no association between phospho-Akt and survival has been
observed (Ermoian et al, 2002; Wang et al, 2005). In prostate
cancer phospho-Akt has also been associated with poor outcome
(Ayala et al, 2004; Kreisberg et al, 2004). In contrast to our
observations, these two studies described phospho-Akt as a strong
predictor of disease recurrence. While we also observed an
association between phospho-Akt expression and PSA relapse in
our study this association was weak. Difference in choice of
patient cohorts easily explains these results since here we included
a considerable number of patients with positive surgical margin
(50% of our cohort) and the follow-up of our patients was longer
(over 5 years). Altogether, our study is in agreement that phospho-
Akt is a predictor of recurrence but seems to be a weaker predictor
than Akt-1 and than pathological parameters such as surgical
margins or pathological stage.
Our study shows a differential role for each isoform of AKT in
the progression of prostate cancer. Based on this data we propose
that Akt may play an important role in the biology of prostate
cancer progression and suggests that Akt may eventually become a
promising therapeutic target.
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Figure 3 Kaplan–Meier PSA recurrence-free survival curve in patients with prostate cancer. n¼Number of patients. Significance (P) is indicated by log
rank (A) cytoplasmic Akt-1 in cancerous tissues. (B) cytoplasmic Akt-2 in cancerous tissues in cancerous tissues. (C) Cytoplasmic Akt-3 in cancerous tissues.
(D) Cytoplasmic phospho-Akt. (E) Nuclear Akt-1 in cancerous tissues. (F) High-risk patients (high cytoplasmic Akt-1/absence of nuclear Akt-1),
intermediate risk patients (high cytoplasmic Akt-1/nuclear Akt-1 and low cytoplasmic Akt-1/absence of nuclear Akt-1), low-risk patients (low cytoplasmic
Akt-1/Akt-1 nuclear).
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